Opportunity for Ontario Cancer Researchers to vie for the “Ernsting Entrepreneurship Award”

Falcons’ Fortunes invites Ontario-based entrepreneurs working in the oncology space to pitch innovative research ideas to an external panel of judges. Hosted by FACIT, the annual Falcons’ Fortunes pitch competition invites Ontario-based entrepreneurs working in the oncology space to pitch innovative research ideas to an external panel of judges.

New for 2022: To continue to help fill Ontario’s seed capital gap, the value of the prize has been increased to $100,000 from FACIT’s Prospects Fund.

While the research idea must be novel and sound (and is subject to further due diligence after the event), the competition is for the best pitch i.e. the presentation that best convinces the investor judging panel on the value of the idea and how $100,000 would improve and/or better illustrate the potential, and if possible commercial, value of the innovative idea itself.

The Falcons’ Fortunes event endeavours to enhance, support and celebrate a culture of commercialization in Ontario, such as the cultivation of skill sets that enable ideas to be successfully pitched to investors and promotion of entrepreneurial spirit.

“Thank you so much and the whole FACIT team, along with the judges, for organizing such a fantastic event. Every pitch was unique and very impactful, and I felt they all deserve to win. I am honoured and ecstatic to receive this award…. I am so proud to be a Canadian citizen (since 2012) living in Ontario. The support and the environment for innovation are amazing, so thank you and FACIT for this opportunity. It is a dream come true for me.”

Run Ze Gao, Co-founder of Air Microfluidic Systems Inc, 2021 Falcons’ Fortunes Winner

The next Falcons’ Fortunes pitch competition is on Friday, February 4th, 2022.

How to participate 

Send an email to Lisa Milestone by Friday, November 19th, 2021 to indicate your intent to participate. An abstract of your pitch idea must be submitted by Friday, December 3rd, 2021 (instructions on submitting abstracts will be emailed to participants). A maximum of 6 participants will be selected by Thursday, December 16th, 2021 to deliver their pitches on Friday, February 4th, 2022.

Eligibility:

Ontario-based academic researchers and start-ups with a cancer-related research idea or innovation.

Format:

Selected participants will give 10-minute pitch presentations to the panel of investors, followed by 5-minutes of Q&A. The objective is to share your big picture idea and convince the panel that an investment of Prospects funding will contribute to moving the idea forward. The pitch should tell a story and highlight (at minimum): 

  • The research idea and associated technology (what is it, what does it do)
  • The need or issue addressed (what is the problem)
  • The target audience/customer (addressable market)
  • What the investment will do to advance the idea (use of proceeds) 
  • Commercial relevance of project (why is it commercially suited/important)
  • Any supporting data or relevant demo

Other additional considerations for the presentation (i.e. preparation for the Q&A) include an understanding of the market potential, IP position or challenges, and what areas of expertise are being sought that members of the investment panel may possess and could provide.

Support Available: 

The FACIT team will provide pitch preparation resources leading up to the event.

Summary of Timeline:

Notice of intent to participate – email RSVP sufficientFri, Nov 19
Submission of pitch abstracts Fri, Dec 3
Announcement of selected pitch candidatesThurs, Dec 16 
Pitch preparation webinarWed, Jan 12
1:1 coaching sessions for finalistsMon, Jan 24
Brief run through for finalistsWed, Feb 2
Falcons’ Fortunes eventFri, Feb 4

    QUESTIONS?

    For more details about the competition, contact us for more information.

    Projects Recently Funded By Falcons’ Fortunes

    Expand your search and review with the Open Search Tool or learn more about the examples of recent Falcon’s Fortunes funded projects below.

    SEARCH FILTERS:

    Innovation Type
    Cancer Type
    Current Funding Stage
    FACIT Fund


    Sort by:

    Xpan Inc

    Innovation Type:
    Medical Technologies
    Cancer Type:
    Multiple
    Funding Stage:
    Seed
    Fund:
    Compass Rose, Falcons’ Fortunes, Prospects
    Developing A Less Invasive Access Port To Maximize The Potential Of Laparoscopic Surgical Oncology

    Bridge7 Oncology

    Innovation Type:
    Informatics & AI
    Cancer Type:
    Multiple
    Funding Stage:
    Proof of Concept
    Fund:
    Falcons’ Fortunes, Prospects
    Scaling clinical expertise with AI to automate and improve the delivery of cancer care.

    Polumiros

    Innovation Type:
    Medical Technologies
    Cancer Type:
    Breast
    Funding Stage:
    Seed
    Fund:
    Falcons’ Fortunes
    ReFilx, a Polymeric Soft Tissue Filler for the Permanent Restoration of Breast Tissue Defects following Lumpectomy

    Air Microfluidic Systems Inc.

    Innovation Type:
    Medical Technologies
    Cancer Type:
    Breast
    Funding Stage:
    Proof of Concept
    Fund:
    Falcons’ Fortunes
    Air microfluidics-enabled active compression sleeve for treating breast cancer-related lymphedema

    Western University (Tenomix)

    Innovation Type:
    Diagnostics
    Cancer Type:
    Other
    Funding Stage:
    Proof of Concept
    Fund:
    Prospects
    A bench-top ultrasound-based device that can automate the detection of lymph nodes in resected colorectal cancer tissue

    Sunnybrook Research Institute

    Innovation Type:
    Diagnostics
    Cancer Type:
    Prostate
    Funding Stage:
    Proof of Concept
    Fund:
    Prospects
    At-home prostate cancer screening kit

    Replica Analytics

    Innovation Type:
    Informatics & AI
    Cancer Type:
    Multiple
    Funding Stage:
    Proof of Concept
    Fund:
    Prospects
    Modeling software to create synthetic data based on real clinical datasets

    Multimagnetics Inc.

    Innovation Type:
    Medical Technologies
    Cancer Type:
    Breast
    Funding Stage:
    Proof of Concept
    Fund:
    Prospects
    Hand-held photoacoustic device to detect tumour margins and residual disease in the surgical cavity during breast-conserving surgery

    University of Toronto

    Innovation Type:
    Therapeutics
    Cancer Type:
    Multiple
    Funding Stage:
    Proof of Concept
    Fund:
    Prospects
    Development of small-molecule inhibitors of mitochondrial RNA polymerase (POLRMT) as an anticancer strategy

    Radiant Biotherapeutics

    Innovation Type:
    Therapeutics
    Cancer Type:
    Multiple
    Funding Stage:
    Proof of Concept
    Fund:
    Compass Rose
    Multivalent, multi-specific antibody nanoparticle platform for therapeutic development

    Cellular Analytics

    Innovation Type:
    Diagnostics
    Cancer Type:
    Multiple
    Funding Stage:
    Seed
    Fund:
    Compass Rose
    Microfluidic platform and lung cancer biomarker chip used to match patients with the most effective therapy for improved treatment outcomes.

    OICR

    Innovation Type:
    Therapeutics
    Cancer Type:
    Multiple
    Funding Stage:
    Proof of Concept
    Fund:
    Prospects
    WD Repeat Platform

    Sunnybrook Research Institute

    Innovation Type:
    Diagnostics
    Cancer Type:
    Multiple
    Funding Stage:
    Proof of Concept
    Fund:
    Prospects
    Algorithm to predict breast cancer patient response to neoadjuvant chemotherapy

    University of Toronto (Perturba)

    Innovation Type:
    Medical Technologies
    Cancer Type:
    Multiple
    Funding Stage:
    Proof of Concept
    Fund:
    Prospects
    Split Intein-Mediated Protein Ligation (SIMPL): a unique and disruptive system for detecting PPIs in real time

    Talon Pharma

    Innovation Type:
    Therapeutics
    Cancer Type:
    Heme
    Funding Stage:
    Proof of Concept
    Fund:
    Prospects
    Inhibition of Kv1.3: Inducing Apoptosis and Impeding Cancer Cell Proliferation

    CCRM (Notch Therapeutics)

    Innovation Type:
    Therapeutics
    Cancer Type:
    Multiple
    Funding Stage:
    Proof of Concept
    Fund:
    Prospects
    A Method for Generating Progenitor T-Cells from Stem and/or Progenitor Cells for Universal CAR-T Therapy

    OICR

    Innovation Type:
    Therapeutics
    Cancer Type:
    Multiple
    Funding Stage:
    Proof of Concept
    Fund:
    Prospects
    ADC-Linker Platform

    Nanology

    Innovation Type:
    Medical Technologies
    Cancer Type:
    Multiple
    Funding Stage:
    Seed
    Fund:
    Compass Rose, Prospects
    A novel nano-theranostic platform technology with capabilities to simultaneously enhance MRI contrast signal in the tumor and enhance the radiation therapy efficacy

    16-Bit

    Innovation Type:
    Informatics & AI
    Cancer Type:
    Breast
    Funding Stage:
    Seed
    Fund:
    Prospects
    Automatic Analysis of Screening Mammograms for Breast Cancer

    DNAStack

    Innovation Type:
    Informatics & AI
    Cancer Type:
    Multiple
    Funding Stage:
    Seed
    Fund:
    Compass Rose, Prospects
    Development of a Cloud Platform for Genomics Data Management, Analysis and Sharing

    Dalriada Therapeutics

    Innovation Type:
    Therapeutics
    Cancer Type:
    Heme
    Funding Stage:
    Seed
    Fund:
    Prospects
    Development of DT-1 Class of Small Molecules for the Treatment of Leukemia

    KA Imaging

    Innovation Type:
    Medical Technologies
    Cancer Type:
    Other
    Funding Stage:
    Seed
    Fund:
    Prospects
    Multi-spectral Digital X-ray Imager

    Radialis Medical

    Innovation Type:
    Medical Technologies
    Cancer Type:
    Breast
    Funding Stage:
    Seed
    Fund:
    Prospects
    Positron Emission Mammography (PEM) Imaging System to Detect Pre-Invasive Breast Cancers

    University of Ottawa

    Innovation Type:
    Therapeutics
    Cancer Type:
    pancreas
    Funding Stage:
    Proof of Concept
    Fund:
    Falcons’ Fortunes
    Development of a Multi-mechanistic Vaccinia Virus-based Platform for the Treatment of Pancreatic Cancer

    OICR

    Innovation Type:
    Diagnostics
    Cancer Type:
    Breast
    Funding Stage:
    Proof of Concept
    Fund:
    Prospects
    Molecular Profiling for Anthracycline Sensitivity in Patients receiving Chemo for Breast Cancer

    Realist Pharma

    Innovation Type:
    Therapeutics
    Cancer Type:
    Multiple
    Funding Stage:
    Seed
    Fund:
    Prospects
    Evaluation of survival benefit and preclinical proof of concept of a novel ganglioside-based cancer vaccine.

    Talon Pharma

    Innovation Type:
    Therapeutics
    Cancer Type:
    Heme
    Funding Stage:
    Proof of Concept
    Fund:
    Prospects
    Cell Permeable KV1.3 Antagonists: Novel Targeting of Apoptosis in Cancer Treatment

    Queens University

    Innovation Type:
    Therapeutics
    Cancer Type:
    Heme
    Funding Stage:
    Proof of Concept
    Fund:
    Prospects
    Development of Novel CYP26 Inhibitors for the treatment of AML

    Fusion Pharmaceuticals Inc.

    Innovation Type:
    Therapeutics
    Cancer Type:
    Multiple
    Funding Stage:
    Exit
    Fund:
    Compass Rose
    Next-generation radiopharmaceuticals for precision medicine (antibody Conjugate for Lung Cancer), prividing a safer approach to targeted radiotherapy by helping the drug clear from normal, healthy tissues and reducing toxicity.

    Novera Therapeutics Inc.

    Innovation Type:
    Therapeutics
    Cancer Type:
    Heme
    Funding Stage:
    Seed
    Fund:
    Compass Rose
    Development of BCL6 Inhibitors for Treatment of Hematological Cancers

    FocusOnCare

    Innovation Type:
    Informatics & AI
    Cancer Type:
    Multiple
    Funding Stage:
    Proof of Concept
    Fund:
    Falcons’ Fortunes
    ChemoTracker App Development

    Capnostics

    Innovation Type:
    Medical Technologies
    Cancer Type:
    Other
    Funding Stage:
    Proof of Concept
    Fund:
    Prospects
    Resurrection of the FDA File and Manufaturing of CellMate Product for Esophageal Cell Sampling

    Sunnybrook Research Institute

    Innovation Type:
    Medical Technologies
    Cancer Type:
    Breast
    Funding Stage:
    Proof of Concept
    Fund:
    Prospects
    External Clinical Validation Study of a Quantitative Ultrasound Spectral Analysis Platform For Monitoring Tumor Response In Women Receiving Neoadjuvent Chemotherapy for Locally Advanced Breast Cancer

    OICR

    Innovation Type:
    Diagnostics
    Cancer Type:
    Breast
    Funding Stage:
    Proof of Concept
    Fund:
    Prospects
    Ring Study to Evaluate the PRedicTive brEast Cancer Test (PRoTECT)

    Sunnybrook Research Institute

    Innovation Type:
    Therapeutics
    Cancer Type:
    Breast
    Funding Stage:
    Proof of Concept
    Fund:
    Prospects
    Evaluation of immune responses engendered in CEA transgenic mice by a vaccine formulation composed of a recombinant CEA N domain antigen and GSK AS15 adjuvant

    Ziliomics

    Innovation Type:
    Informatics & AI
    Cancer Type:
    Multiple
    Funding Stage:
    Proof of Concept
    Fund:
    Compass Rose, Prospects
    Development of Heliotrope Bioinformatics Software Platform

    Sunnybrook Research Institute

    Innovation Type:
    Medical Technologies
    Cancer Type:
    Multiple
    Funding Stage:
    Proof of Concept
    Fund:
    Falcons’ Fortunes
    Ultra-Low Dose Microbubbles for Cancer

    OICR

    Innovation Type:
    Therapeutics
    Cancer Type:
    Multiple
    Funding Stage:
    Proof of Concept
    Fund:
    Prospects
    Fully synthetic, self-adjuvanting vaccines incorporating tumor-associated antigenic epitopes for cancer immunotherapy

    Turnstone Biologics Inc.

    Innovation Type:
    Therapeutics
    Cancer Type:
    Multiple
    Funding Stage:
    Series A,B,C
    Fund:
    Compass Rose
    Transforming patient care with a new class of targeted viral immunotherapies to fight cancer (Marabavirus-based oncolytic viral vector)

    Fluorinov Pharma (Trillium)

    Innovation Type:
    Therapeutics
    Cancer Type:
    Heme
    Funding Stage:
    Exit
    Fund:
    Compass Rose
    FV162 Oral Proteasome Inhibitor

    OICR (Cellax)

    Innovation Type:
    Therapeutics
    Cancer Type:
    pancreas
    Funding Stage:
    Proof of Concept
    Fund:
    Compass Rose
    Cellax Nanoparticles for Enhanced Cancer Treatment

    XLV Diagnostics

    Innovation Type:
    Medical Technologies
    Cancer Type:
    Breast
    Funding Stage:
    Series A,B,C
    Fund:
    Compass Rose
    X-ray light valve (XLV) for low-cost digital mammography

    Privacy Analytics

    Innovation Type:
    Informatics & AI
    Cancer Type:
    Multiple
    Funding Stage:
    Exit
    Fund:
    Compass Rose
    Software unlocking the vast potential of medical data without compromising individual privacy or causing unacceptable distortion of the data

    Harmonic Medical

    Innovation Type:
    Medical Technologies
    Cancer Type:
    Liver
    Funding Stage:
    Series A,B,C
    Fund:
    Compass Rose
    A system using ultrasound to both detect and treat tumours in bone and liver for the relief of pain without surgery and without expensive imaging equipment.

    McMaster University

    Innovation Type:
    Therapeutics
    Cancer Type:
    Multiple
    Funding Stage:
    Proof of Concept
    Fund:
    Compass Rose
    Development of Radiolabeled Insulin Probe

    Triphase Accelerator Corporation

    Innovation Type:
    Therapeutics
    Cancer Type:
    Multiple
    Funding Stage:
    Series A,B,C
    Fund:
    Compass Rose
    Formation of an Accelerator enterprise designed to take drug candidates from IND through to clinical proof-of-concept. Later decided to accept pre-IND assets as well.

    Univeristy of Toronto (Kapplex)

    Innovation Type:
    Medical Technologies
    Cancer Type:
    Multiple
    Funding Stage:
    Exit
    Fund:
    Compass Rose
    A Digital Microfluidics Platform for High-Throughput Apoptosis Screening

    Xagenic

    Innovation Type:
    Medical Technologies
    Cancer Type:
    Multiple
    Funding Stage:
    Series A,B,C
    Fund:
    Compass Rose
    Validation of the GenEplex platform for clinically accepted leukemia biomarkers

    DLVR Therapeutics

    Innovation Type:
    Therapeutics
    Cancer Type:
    Liver
    Funding Stage:
    Proof of Concept
    Fund:
    Compass Rose
    Novel nanoparticle delivery technology.

    University of Toronto (Receptor-OncoTek)

    Innovation Type:
    Therapeutics
    Cancer Type:
    Other
    Funding Stage:
    Proof of Concept
    Fund:
    Compass Rose
    Preclinical development of PoLi-PTX, Intraperitoneal Ovarian Cancer Therapy

    DVS Sciences (Fluidigm)

    Innovation Type:
    Medical Technologies
    Cancer Type:
    Multiple
    Funding Stage:
    Exit
    Fund:
    Compass Rose
    Flow cytometer-mass spectrometer for multi-parametric cell and bead analysis

    UHN (TorCell Therapeutics)

    Innovation Type:
    Therapeutics
    Cancer Type:
    Heme
    Funding Stage:
    Proof of Concept
    Fund:
    Compass Rose
    Novel T-cell Immunotherapy (autologous cellular therapy)

    UHN

    Innovation Type:
    Therapeutics
    Cancer Type:
    Heme
    Funding Stage:
    Proof of Concept
    Fund:
    Compass Rose
    Development of novel chemical proteosome inhibitors

    Sunnybrook Research Institute

    Innovation Type:
    Diagnostics
    Cancer Type:
    Liver
    Funding Stage:
    Proof of Concept
    Fund:
    Compass Rose
    Glypican-3: a novel marker for the early diagnosis of hepatocellular carcinoma

    UHN

    Innovation Type:
    Medical Technologies
    Cancer Type:
    Liver
    Funding Stage:
    Proof of Concept
    Fund:
    Compass Rose
    Novel Radio Frequency Ablation Technology for Treatment of Solid Tumours

    ArcticDx

    Innovation Type:
    Diagnostics
    Cancer Type:
    Other
    Funding Stage:
    Proof of Concept
    Fund:
    Compass Rose
    Development of a colon cancer risk prediction diagnostic tool

    Robarts Research Institute

    Innovation Type:
    Medical Technologies
    Cancer Type:
    Prostate
    Funding Stage:
    Proof of Concept
    Fund:
    Compass Rose
    3D ultrasound-guided intraoperative and dynamic minimally invasive trans-perineal prostate therapy and biopsy platform

    Naming of the Ernsting Entrepreneurship Award


    In 2016, the Falcons’ Fortunes prize was named the “Ernsting Entrepreneurship Award” in honour of Dr. Mark Ernsting, Senior Biomedical Engineer at the Ontario Institute for Cancer Research whose life was tragically cut short in December 2015. Mark exemplified the entrepreneurial spirit that FACIT strives to build and support within Ontario.